Overview

Radium-223 in Combination With Enzalutamide

Status:
Active, not recruiting
Trial end date:
2022-12-01
Target enrollment:
Participant gender:
Summary
This study aims to determine the safety and tolerability of Radium-223 when administered in combination with enzalutamide in progressive metastatic castrate-resistant prostate cancer.
Phase:
Phase 2
Details
Lead Sponsor:
Cancer Trials Ireland